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ABSTRACT
Attention-deficit and hyperactivity disorder (ADHD) is a common childhood disorder with a 
substantial genetic component. However, the extent to which epigenetic mechanisms play 
a role in the etiology of the disorder is not known. We performed epigenome-wide 
association studies (EWAS) within the Pregnancy And Childhood Epigenetics (PACE) 
Consortium to identify DNA methylation sites associated with ADHD symptoms at two 
methylation assessment periods: birth and school-age. We examined associations of DNA 
methylation in cord blood with repeatedly assessed ADHD symptoms (age range 4-15 
years) in 2477 children from five cohorts and DNA methylation at school-age with 
concurrent ADHD symptoms (age 7-11 years) in 2374 children from ten cohorts. The 
regression estimates at nominal significance of the two EWAS (birth and school-age 
methylation) correlated (ρ=0.30) between both time points. At birth, we identified nine 
probes that were associated with later ADHD symptoms at genome-wide significance, 
including ERC2 and CREB5. Peripheral blood DNA methylation at one of these probes 
(cg01271805 located in the promotor region of ERC2, which regulates neurotransmitter 
release) was previously associated with brain methylation. Another genome-wide 
significant probe (cg25520701) lies within the gene body of CREB5, which was associated
with neurite outgrowth and an ADHD diagnosis in previous studies. In contrast, no probes 
reached genome-wide significance when ADHD was associated with school-age DNA 
methylation. In conclusion, DNA methylation at birth is associated with ADHD. Future 
studies are needed to confirm the utility of methylation variation as biomarker and its 
involvement in causal pathways.
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Introduction
Attention-deficit and hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder characterized by impulsivity, excessive activity and attention 
problems. Symptoms often become apparent during school-age with a world-wide 
prevalence of 5-7.5%.1 Genetic heritability is estimated between 64%-88%.2,3 Additionally 
several environmental factors are suspected to impact ADHD, e.g. prenatal maternal 
smoking or lead exposure.4–7 However, the genetics and environmental pathways that 
contribute to ADHD risk remain unclear. A possibility is that DNA methylation, an 
epigenetic mechanism that regulates gene expression, may mediate genetic or 
environmental effects.
Several studies have investigated DNA methylation in relation to ADHD diagnoses 
or symptoms using either a candidate approach or epigenome-wide association studies 
(EWAS) in peripheral blood and saliva tissue.8,9 A leading hypothesis concerning the 
etiology of ADHD suggests that deficiencies in the dopamine system of the brain have an 
impact on ADHD development.4,10 Consequently, candidate studies have primarily focused 
on genes related to dopamine function. For instance, DNA methylation alterations in 
DRD411–13, DRD512, and DAT112,14 genes have been associated with ADHD diagnoses or 
symptoms, though not consistently15. Beyond the candidate gene approach, three studies 
tested DNA methylation across the whole genome. One study performed an EWAS in 
school-aged children using a case-control design.16 The study identified differentially 
methylated probes in VIPR2, a gene expressed in the caudate and previously associated 
with psychopathology. Another EWAS investigated DNA methylation at birth and at 7 years
of age.17 At birth 13 probes located in SKI, ZNF544, ST3GAL3 and PEX2 were found to be
associated with ADHD trajectories from age 7 to 15 years. Interestingly, cross-sectionally 
6
.CC-BY 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted October 16, 2019. . https://doi.org/10.1101/806844doi: bioRxiv preprint 
the methylation status of these probes at age 7 was not associated with ADHD. An EWAS 
in adulthood failed to find any differentially methylated sites.18
While considerable research has begun to investigate DNA methylation in relation 
to ADHD, large multi-center epigenome-wide studies, which allow for increased power and
generalizability, are lacking in childhood. Here we performed the first epigenome-wide 
prospective meta-analysis to identify DNA methylation sites associated with childhood 
ADHD symptoms employing cohorts from the Pregnancy And Childhood Epigenetics 
(PACE) Consortium19. Since the temporal stability of methylation potentially associated 
with ADHD symptoms is unclear, we tested DNA methylation both at birth using cord blood
and in school-age (age 7-9 years) using DNA derived from peripheral whole blood. In the 
analyses of methylation at birth, the aim was to predict ADHD symptoms between ages 4 
and 15 years. We took advantage of the fact that many participating cohorts assessed 
ADHD repeatedly and employed a repeated measures design to increase precision. 
Furthermore, we utilized data in childhood to examine cross-sectional DNA methylation 
patterns associated with ADHD symptoms at school age.
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Methods
This study consists of two parts: the birth methylation EWAS and the school-age 
methylation EWAS described successively below.
Birth Methylation EWAS
Participants
Five cohorts (Avon Longitudinal Study of Parents and Children (ALSPAC),20–22 Generation 
R (GENR),23 INfancia y Medio Ambiente (INMA),24 Newborn Epigenetic Study 
(NEST)25,26 and Prediction and prevention of preeclampsia and intrauterine growth 
restriction (PREDO)27) in the PACE consortium had information on DNA methylation in 
cord blood and ADHD symptoms. These cohorts have a combined sample size of 2477 
(Table 1). Participants were mostly of European ancestry, except for NEST, an American 
cohort which also included participants of African ancestry. Both ancestries were treated 
as separate cohorts in the meta-analysis to account for heterogeneity.
DNA Methylation and QC
DNA methylation was measured at birth in cord blood. The Illumina Infinium 
HumanMethylation450K BeadChip was used to interrogate CpG probes in all cohorts. 
(Table S1). Methylation levels outside of the lower quartile minus 3*interquartile or upper 
quartile plus 3*interquartile range were removed. Each cohort ran the EWAS separately 
and results were meta-analyzed. The distribution of the regression estimates and p-values 
were examined for each study and pooled results. Deviations from a normal distribution of 
regression estimates or a higher number of low p-values than expected by chance may be 
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signs of residual confounding, but may also be the result of a true poly-epigenetic signal. 
To help in interpretation of the results, we used the BACON method.28 BACON analyzes 
the distribution of regression coefficients and estimates an empirical null distribution. 
Results can then be compared against the empirical null, which already includes biases, 
rather than the theoretical null. We excluded CpG probes, that were available in less than 
four cohorts, fewer than 1000 participants, and allosomal probes, due to the complex 
interpretation of dosage compensation.
ADHD Symptoms
ADHD symptoms were measured when children were 4-15 years old (depending on the 
cohort) with parent-rated instruments, specifically the Behavior Assessment System for 
Children (BASC),29 Child Behavior Checklist (CBCL),30,31 Conners32 and the Development 
and Well-Being Assessment (DAWBA)33 (Table S2). If a cohort had ADHD symptoms 
measured repeatedly (3 cohorts), every assessment wave was jointly analyzed in a mixed 
model (see statistical analysis). The repeated measure design increased the precision of 
the ADHD severity estimate and sample size, since missing data in one or two of the 
assessments can be handled with maximum likelihood. Given the variety of instruments 
used within and across cohorts, all ADHD scores were z-score standardized to enable 
meta-analysis. 
Statistical analysis
Cohorts with repeated ADHD assessment were analyzed using linear mixed models, with 
z-scores of ADHD symptoms as the outcome and methylation (in betas) as the main 
predictor. Each CpG probe was analyzed separately and adjusted for multiple correction 
using Bonferroni adjustment. We used a random intercept on the participant and batch 
level, to account for clustering due to repeated measures and batch effects. The following 
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potential confounders were included as fixed effects: maternal age, educational level, 
smoking status (yes vs no during pregnancy), gestational age, sex, and estimated white 
blood cell proportions (Bakulski reference estimated with the Houseman method).34 Mixed 
models were fitted using restricted maximum likelihood. We used R35 with the 
lme436 package to estimate the models. Cohorts with a single ADHD assessment wave 
used a model without random effects or only on batch level, depending on analyst 
preference.
Meta-analysis was performed using the Han and Eskin random effects model.37 This
model does not assume that true effects are homogeneous between cohorts, however, it 
does assume that null effects are homogeneous. This modified version of the random 
effect model has comparable power to a fixed effects analysis, while better accounting for 
study heterogeneity, such as ancestry differences, in simulation studies.37 Genome-wide 
significance was defined at the Bonferroni-adjustment threshold of p<1E-07, suggestive 
significance at p<1E-05, and nominal significance at p<0.05.
Follow-up analyses
We performed several look-ups of genome-wide significant probes. We used the 
BECon database38 to check the correlation between peripheral and brain methylation 
levels in post-mortem tissue. To test genetic influence we interrogated the genome-wide 
significant probes in MeQTL39 and twin heritability databases.40  We also attempted to 
replicate genome-wide significant probes reported in a previous EWAS from the ALSPAC 
study.17 For replication we reran the meta-analysis without the ALSPAC cohort. To quantify 
the variance explained by genome-wide significant probes, we predicted ADHD scores at 
age 8 in Generation R by all meta-analytically genome-wide significant probes with 10-fold 
cross-validation and 100 repetitions. 
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Pathway Analysis
We performed pathway enrichment analysis with the missMethylpackage41 on 
suggestive probes (P<1E-05). We used as references: gene ontology (GO), KEGG and 
curated gene sets (C2; http://software.broadinstitute.org/
gsea/msigdb/collections.jsp#C2) from the Broad Institute Molecular signatures database42. 
P-values were adjusted for the number of CpGs associated with each gene43 and false 
discovery rate.
To test enrichment for regulatory features (gene relative position, CpG island 
relative position and blood chromatin states) we applied χ2 tests. Enrichment tests were 
performed for all CpGs, and for hypo and hypermethylated CpGs separately. CpG 
annotation was performed with the IlluminaHumanMethylation450kanno.ilmn-12.hg19 R 
package.44 Annotation to 15 chromatin states was retrieved from 27 blood cell types from 
the Roadmap Epigenomics Project web portal (https://egg2.wustl.edu/
roadmap/web_portal/). Each CpG in the array was annotated to one or several chromatin 
states by defining a state as present in those loci if it was described in at least 1 of 27 cell 
types. See supplementary information 1 for full description.
School-age methylation EWAS
Participants
Four cohorts (ALSPAC, GENR, HELIX45 and GLAKU46) with a combined sample size of 
2374 joined the school-age methylation EWAS (Table 1). HELIX consists of six sub-
cohorts, which were pre-processed and analyzed jointly.45 All cohorts had participants of 
European ancestry, except HELIX, which also included participants with a Pakistani 
background living in the UK, which were treated as a separate cohort in the meta-analysis.
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Fifty-three percent of participants in the school-age EWAS were also part of the birth 
EWAS.
DNA Methylation and QC
DNA methylation was measured at ages 7-12 using peripheral whole blood. The Illumina 
Infinium HumanMethylation450K BeadChip and Infinium MethylationEPIC Kit (GLAKU) 
were used to interrogate CpG probes. QC steps were identical to the birth methylation 
EWAS.
ADHD Symptoms
ADHD symptoms were measured at the same age as DNA methylation (age 7-11 years) 
using the parent-rated measures DAWBA and CBCL (Table S2). In contrast to the birth 
methylation EWAS only the assessment closest to the DNA methylation assessment age 
was analyzed.
Statistical analysis
The statistical model was similar to the model used in the birth methylation EWAS. 
However, cell counts were estimated with the Houseman method using the Reinius 
reference.47 Since the outcome was not repeated, there was no random effect on the 
participant level. We also added assessment age as covariate. The meta-analysis 
methods were identical to the birth methylation EWAS. 
Follow-up analyses
As we observed an overall low signal, we did not perform follow-up analyses. 
However, we attempted to replicate six probes identified as most suggestive in a previous 
case-control EWAS in school-age.16
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Results
Birth Cord Blood Methylation
EWAS Quality Check
Four out of the six cohorts showed a high λ, indicating larger number of low p-
values than expected under the null (Table 1). BACON analysis suggested that the 
majority of the inflation was due to a true signal, as indicated by inflation values clearly 
lower than λ. To test the impact of sample size on λ, we restricted the GENR sample 
randomly to 900 and 1100 participants, resulting 812 and 991 participants due to missing 
covariates. The lambdas were 0.96, 1.21, 1.51 for 812, 991, and 1191 participants. We 
thus conclude that the over-representation of low p-values is mostly due to power.
The BACON analyses also indicated a trend towards positive/negative values in 
some of the datasets, which might indicate confounding, e.g. by population stratification. 
To test this, we added principal components of ancestry in GENR and ALSPAC, but these 
did not meaningfully change results.
We conducted the meta-analysis under the assumption that any such biases will be 
corrected in the pooled analysis, since they were not homogeneous across cohorts. 
Indeed, the pooled estimates did not show a trend towards positive or negative regression 
estimates (Median=0.02), only an overrepresentation of low p-values (λ=1.86, see QQ Plot
in Figure 1). The BACON estimates for inflation, however, suggested that these are mostly
due to a true signal (Inflation=1.1).
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Single Probe Analysis
After QC, 472,817 CpG sites remained for analysis. Results of the meta-analysis of 
cord blood EWAs are shown in Figure 2. Nine CpG sites showed genome-wide 
significance (p<1E-07, Table 2). ADHD symptoms were between 0.16SD (SE=0.03) and 
0.44SD (SE= 0.12) higher with 10% lower methylation at these probes. Eight probes out of
nine that were available in the BECon database38 are typically methylated in both whole 
blood as well as in the brain (Figures 3, S1 and S2). A lookup in the BECon database 
revealed that the CpG site cg01271805 in the promoter region of gene ERC2 shows 
variable methylation in three brain regions (BA10, BA20, BA7). Importantly, methylation 
levels in the brain are moderately correlated with whole blood methylation (ρ=0.33-0.46) 
(Figure 3), suggesting that peripheral cg01271805 methylation levels could be a useful 
marker for brain methylation levels. The other seven genome-wide significant probes 
showed less consistent correlations between blood and brain tissues and associated 
genes had less specificity for expression in the brain, based on GTEx48 data. No SNP was 
associated with our nine top CpG probes when accounting for linkage disequilibrium 
according to the MeQTL database39. Furthermore, all nine probes had a twin heritability 
below 20% in a previous study (Table S3).40 After adjusting for inflation and bias with 
BACON, only one CpG remained statistically significant (cg25520701, CREB5, ß =-3.54, 
SE = 0.66, p = 9.59E-08). It should be noted, that the BACON adjusted p-values rely on 
statistics from the traditional random effects model. With the traditional model, only 
cg25520701, cg09762907 and cg22997238 remained genome-wide significant. Thus the 
difference in p-value is not solely the result of adjustment for the inflation, but also the use 
of more conservative tests. In Generation R, the joint explained variance of ADHD scores 
at age 8 by the genome-wide significant probes was 1.8% (R2 from 10-fold repeated cross-
validation).
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Pathway Analysis
Two-hundred forty-nine probes showed suggestive (P<1E-05) associations and 
were annotated to 182 unique genes. In gene-based analyses no pathway survived 
multiple testing correction. See supplementary materials for full results.
 Suggestive CpGs were enriched in intergenic regions. Of these, hypomethylated 
probes were enriched for 3’UTR regions and depleted for TSS200 and first exon regions, 
open sea, north shelf and south shelf regions, south shore and islands. Regarding 
chromatin states, hypomethylated probes showed an enrichment for transcription (Tx and 
TxWk), quiescent positions and depletion for transcription start site positions (TSSA, 
TxFlnk, TxFlnk), bivalent (EnhBiv) and repressor (ReprPC) positions. Hypermethylated 
probes showed the opposite chromatine state patterns. See supplementary information 1 
for full results.
Replication of previous EWAS
We attempted to replicate findings for 13 CpGs, at which DNA methylation at birth 
was associated with ADHD trajectories.17 However, no probe survived multiple-testing 
correction with incosistent effect directions. (Table S4).
School-age methylation
EWAS Quality Checks
The beta regression distribution showed no signs of errors, but three out of the five 
cohorts showed a trend towards positive associations in separate analyses (Table 1). The 
lambda was below 1.11 for all cohorts. BACON suggested no inflation of the test statistics 
due to confounding or other biases, though the trend towards positive associations 
remained. The pooled results showed a low lambda (0.96), no inflation (0.92) but a slight 
over-representation of positive associations (0.14).
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Single Probe Meta-Analysis
We associated DNA methylation at school-age in whole-blood at 466,574 CpG sites
with ADHD symptoms at the same age. No CpG reached genome-wide significance (all 
p>4.96E-06, Figure 2). Furthermore, none of the loci at which DNA methylation at birth 
was significantly associated with ADHD symptoms, also showed a cross-sectional 
association at school-age (p>0.33). 
Replication of previous EWAS
We attempted to replicate the six most suggestive EWAS probes of a previous 
case-control study.16 While all but one showed a consistent direction, none of the probes 
were statistically significant. (Table S5)
Stability of methylation association across age
The associations between methylation at birth with ADHD symptoms and 
methylation at school-age with ADHD symptoms were largely consistent for nominally 
significant probes. The regression estimates from those CpG sites, which had nominally 
significant associations at birth (p<0.05, n=73,057) correlated with the regression 
estimates of the school-age EWAS (ρ=0.45). When restricting the school-age methylation 
EWAS to those cohorts, which were not featured in the birth methylation EWAS (thus 
excluding overlaps), the correlation remained (ρ=0.30). Vice versa, when filtering for 
probes which were nominally significant at school-age, 23,770 probes remained of which 
4075 overlapped with nominally significant probes at birth. The correlation for this set was 
very similar, ρ=0.47 among all cohorts and ρ=0.35 between independent cohorts (47%).
16
.CC-BY 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted October 16, 2019. . https://doi.org/10.1101/806844doi: bioRxiv preprint 
Discussion
In this population-based study, we performed the first epigenome-wide meta-
analysis of ADHD symptoms in childhood, using two DNA methylation assessments (birth 
and school-age), as well as repeated measures of ADHD symptoms. DNA methylation at 
birth, but not at school-age, was associated with later development of ADHD symptoms 
with genome-wide significance at nine loci. Interestingly all the identified probes showed a 
pattern of a high average rate of methylation in cord blood, where lower levels of 
methylation in an individual were associated with more ADHD symptoms in childhood. 
DNA methylation in cord blood reflects the effects of genetics and the intrauterine 
environment. The results thus suggest that cord blood DNA methylation is a marker for 
some of the ADHD risk factors present before birth or functions as a potential mediator of 
these risk factors. While not impossible, reverse causality at this age is unlikely to explain 
our results, as ADHD only manifests at a later stage of development. 
We analyzed DNA methylation in cord and peripheral blood, which may not 
correspond to the methylation status in the brain. While DNA methylation may affect 
behavior via other pathways, DNA methylation in the brain arguably has the strongest a 
priori likelihood of representing causal mechanisms. Seven out of eight significant probes 
did not show consistent correlation between methylation status in whole blood and post-
mortem brain tissue in a previous study, i.e. DNA methylation levels in blood may not 
represent brain levels and thus associations with ADHD may be different.38 However, one 
of the eight probes (cg01271805) is an exception in that methylation levels in whole blood 
are associated with methylation levels in various brain regions. Importantly, this probe lies 
in the promoter region of the gene ERC2, that is highly expressed in brain tissue. ERC2 
regulates calcium dependent neurotransmitter release in the axonal terminal.50 Specifically,
ERC2 is suspected to increase the sensitivity of voltage dependent calcium channels to 
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hyperpolarization, resulting in higher neurotransmitter release. SNPs in the ERC2 locus 
were previously shown to distinguish schizophrenia and bipolar disorder patients51 and 
have been suggested to impact cognitive functioning52. ERC2 is especially expressed in 
Broadmann area 9 of the frontal cortex.48 Previous imaging studies have demonstrated 
differential activation in this area when children with or without ADHD performed various 
cognitive tasks.53,54 The correlation with brain methylation, the location in a promoter and 
gene expression in the brain make cg01271805 a plausible candidate locus, where 
reduced methylation may be mechanistically involved in ADHD development. We 
hypothesize, that lower methylation levels at cg01271805 increases the expression of 
ERC2, which in turn increases neurotransmitter release, with an adverse impact on the 
development of ADHD symptoms. Another gene with a genome-wide significant probe and
high relevance for neural functioning is CREB5 (cg25520701). CREB5 is expressed in 
fetal brain and the prefrontal cortex, and has been previously related to neurite outgrowth. 
Moreover, SNPs in this gene were associated with ADHD in two recent GWAS.55,56 Thus, it 
is plausible that differences in DNA methylation at this locus may modify ADHD risk during 
development.
While the birth methylation EWAS identified several loci, associating school-age 
methylation with concurrent ADHD symptoms revealed no genome-wide significant 
associations. Furthermore, the overall association signal was lower, despite similar sample
sizes. None of the probes, which were significantly associated at birth showed any 
association when measured at school-age. Given that sample sizes were comparable, this
difference must come from changes in the epigenome or study heterogeneity, rather than 
differences in statistical power. In terms of instrument heterogeneity, the school-age EWAS
was more homogeneous, almost exclusively using CBCL. Additionally, as both EWAS 
feature a mix of several cohorts selected based on the same criteria and around half of the
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participants were represented at both time points, study heterogeneity appears to be an 
unlikely explanation. The stronger signal in the birth EWAS may be considered surprising 
given that typically two measures are typically more strongly associated if measured in 
closer temporal proximity. However, in line with our results Walton et al. also observed in a 
previous EWAS,17 that birth methylation may be a better predictor of later ADHD symptoms
than childhood methylation, possibly reflecting sensitive periods. This may also explain 
why a previous EWAS using DNA methylation in adulthood did not find associations with 
adult ADHD symptoms, despite a much larger sample size compared to this 
EWAS.18 Whether DNA methylation in cord blood has stronger causal effects or is a better 
marker for early life factors cannot be concluded from the present study. Alternatively, 
tissue differences between cord blood and whole blood may account for the differences in 
association pattern. Finally, it is possible that interventions in childhood and other 
environmental influences reduced the initial epigenetic differences at birth between 
children with higher and lower ADHD symptoms.
That said, we observed consistency in the associations of methylation at both 
timepoints with ADHD symptoms. The regression estimates of both EWAS correlated on a 
genome-wide level. This held true, even when cohorts featured in both EWAS (3 cohorts) 
were removed from the analysis suggesting that the association between DNA methylation
at birth and ADHD symptoms remain in school-age to some extent and is consistent 
across independent cohorts.
Strengths of this study include the large sample size, repeated outcome measures, 
extensive control for potential confounders and the use of DNA methylation at two different
time-points, enabling us to characterize both prospective and cross-sectional associations 
with ADHD symptoms. However, several limitations need to be discussed as well. A causal
interpretation of our findings is challenged by the possibility of residual confounding and 
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reverse causality. DNA methylation might be a marker for untested adverse environmental 
factors that could affect ADHD via independent pathways. In addition, children with higher 
ADHD symptoms may evoke a particular environment, which might shape the epigenome 
and be a substantial factor for the cross-sectional analyses in school-age. It is also likely 
that many more CpG sites are associated with ADHD than identified in this study, given the
necessity for stringent multiple testing correction. Larger sample sizes are necessary to 
detect further methylation sites. As is typical for (epi-)genetic studies, the effect size of 
individual top probes was rather small: the joint effect of the genome-wide probes was 
estimated below 2%. However, the strong genome-wide epigenetic signal suggests a 
potential for the development of epigenetic-scores based on birth methylation, which could
lead to early prevention efforts before ADHD symptoms arise.
In summary, we identified nine CpG sites for which lower methylation status at birth 
is associated with later development of ADHD symptoms. The results suggest that DNA 
methylation in ERC2 and CREB5 may exert an influence on ADHD symptoms, potentially 
via modification of neurotransmitter functioning or neurite outgrowth.
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Tables
Table 1: Cohort characteristics of birth methylation EWAS
Standardized regression coefficients BACON estimates
Cohort Ancestry/
Ethnicity
n Methylation 
Age
ADHD Age Instrument 33% 50% 66% λ Inflation Bias
 Birth EWAS
ALSPAC European 714 0 8, 11, 14, 15 DAWBA -0.21 0.25 0.89 1.60 1.10 0.37
GENR European 1191 0 6,8,10 CBCL 
(6,10),
Conners (8)
-0.48 0.01 0.53 1.51 1.20 0.05
INMA European 325 0 7,9 Conners 
(7), CBCL 
(9)
-1.37 -0.40 0.43 0.80 0.87 -0.19
NEST Black 55 0 5 BASC -3.50 -0.03 3.63 1.16 1.10 0.00
NEST White 56 0 5 BASC -2.54 -0.09 2.36 0.80 0.92 -0.01
PREDO European 136 0 5 Conners -1.55 -0.25 1.20 1.45 0.95 0.21
META - 2477 - - - -0.37 0.02 0.42 1.86 1.10 0.01
 School-age EWAS
ALSPAC European 651 7 8 DAWBA -0.61 -0.10 0.54 1.09 1.00 -0.08
GENR European 395 10 10 CBCL -0.93 -0.00 0.98 1.00 0.97 -0.01
GLAKU European 215 12 12 CBCL -0.79 0.31 1.50 0.92 0.96 0.13
HELIX European 1034 8 8 CBCL -0.26 0.47 1.40 1.11 0.98 0.28
HELIX Pakistani 79 7 7 CBCL -1.66 1.86 5.48 0.98 0.96 0.26
Meta - 2374 - - - -0.24 0.14 0.62 0.96 0.92 0.14
n Number of participants
33%, 50%, 66% Quartiles of regression coefficient distribution
λ Inflation of p-values
Inflation Inflation of p-values due to suspected bias
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Bias Trend toward negative/positive distribution of regression coefficients due to suspected bias
Table 2: EWAS Results
Birth methylation School-age methylation
CpG Gene Chr Position nstudies n B SE p nstudies n B SE p
cg25520701 CREB5 7 28800657 6 2450 -3.53 0.60 4.95E-09 5 2279 -0.13 1.09 0.94
cg24838839 Intergenic 5 61031569 6 2468 -4.15 1.79 3.95E-08 5 2287 1.52 1.38 0.33
cg22997238 Intergenic 7 36014218 6 2465 -1.63 0.30 8.81E-08 5 2291 -0.06 0.47 0.94
cg21600027 Intergenic 4 124443502 6 2464 -3.04 0.81 2.64E-08 5 2281 0.98 0.89 0.33
cg17876201 ZBTB38 3 141139991 6 2457 -4.41 1.20 7.58E-09 4 2066 0.56 1.32 0.73
cg11251614 PPIL1 6 36839846 6 2451 -3.43 0.68 3.89E-08 5 2276 0.77 1.52 0.68
cg09762907 TRERF1 6 42290256 6 2460 -2.11 0.39 8.76E-08 5 2284 -0.55 0.64 0.46
cg09158638 Intergenic 16 62309996 6 2470 -2.55 1.40 1.89E-08 5 2270 -0.33 1.04 0.80
cg01271805 ERC2 3 55694954 6 2469 -2.86 1.71 5.24E-08 5 2289 0.28 0.73 0.76
Chr Chromosome
nstudies Number of studies
n Number of participants
B Regression coefficient
SE Standard error
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Figure 1
Fig. 1: Quantile-quantile plot of observed −log10 p-values in the cord blood and school-age 
EWAS vs expected −log10 p-values under assumption of chance findings only. The diagonal 
line represents the distribution of the expected p values under the null. Points above the 
diagonal indicate p-values which are lower than expected.
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Figure 2
Fig. 2.: Manhattan plot of −log10 p values vs SNP position (basepair and chromosome). Red 
line indicates genome-wide significance and blue line suggestive level
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Figure 3
Fig. 3.:  Lookup of brain-blood correlations and variability of genome-wide significant CpG 
sites in the BECon database
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Chr Coor Gene(s) Gene Region(s) Variability Correlation
Cell 
Composition
     BA10 BA20 BA7 Blood BA10 BA20 BA7 Blood Brain
cg22997238
cg09762907
cg11251614
cg24838839
cg21600027
cg17876201
cg01271805
cg09158638
Correlation or Cell Composition Percentile
 or Variability Status
90% (Positive)
75−90% (Positive)
50−75% (Positive)
<50% (Positive)
<50% (Negative)
50−75% (Negative)
75−90% (Negative)
90% (Negative)
90% (Blood Cell Comp.)
75−90% (Blood Cell Comp.)
50−75% (Blood Cell Comp.)
<50% (Blood Cell Comp.)
90% (Brain Cell Comp.)
75−90% (Brain Cell Comp.)
50−75% (Brain Cell Comp.)
<50% (Brain Cell Comp.)
Not Variable
Variable
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